Malaria Information and Prophylaxis, by Country [D]

Print
Related Pages

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Democratic Republic of the Congo (Congo-Kinshasa) All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Denmark None Not Applicable Not Applicable Not Applicable
Djibouti All Chloroquine P. falciparum 60-70%;

P. vivax 30-40%;
P. ovale rare

 Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Dominica None Not Applicable Not Applicable Not Applicable
Dominican Republic Primarily in the provinces near the border with Haiti, and the provinces (including resort areas) of La Altagracia, San Cristobal, San Juan, and Santo Domingo. Transmission in Santo Domingo City (Distrito Nacional), is primarily in the Los Tres Brazos and La Cienaga areas. Rare locally transmitted cases in other provinces. None P. falciparum 100% Provinces near the border with Haiti, and the provinces (including resort areas) of La Altagracia, San Cristobal, San Juan, and Santo Domingo: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, or tafenoquine.

Other areas: None (mosquito avoidance only)6

 

 City(ies) of travel

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2.  Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see: https://www.cdc.gov/malaria/travelers/index.html
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.